TRGNF News and Press, Transgene S.A. From 01/22/24

Strasbourg, France, January 22, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of James Wentworth, PhD, MBA, as Chief Business Officer ...

Strasbourg (France), January 22, 2024 - 08:00 am CET TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2024. March 27, 2024: 2023 Fiscal Year Results May 14, 2024: First Quarter 2024 Financial Results May 15, 2024: Annual Shareholders' Meetin...

Transgene and NEC plan to start an extension of the randomized Phase I trial into a randomized Phase I/II study in 2024 to further demonstrate the potential of TG4050 as an adjuvant treatment of head and neck cancers Strasbourg, France & Tokyo, Japan, January 8, 2024, 5:45 ...

Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Arnaud Dubarry as Chief Financial Officer (CFO), effective January 1, 2024. Arnaud D...

2023-11-08 09:59:18 ET More on Transgene S.A. Transgene SA (TRGNF) Q2 2023 Earnings Call Transcript Historical earnings data for Transgene S.A. Financial information for Transgene S.A. For further details see: Transgene reports Q3 results

Transgene continues to advance its innovative immunotherapy pipeline, with key clinical development catalysts expected in the next 12 months Financial visibility until the end of 2024 Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops v...

The Phase I Part B will evaluate the combination of BT-001 and pembrolizumab in solid tumors, including melanoma Regulatory News: Transgene (Euronext Paris: TNG) , a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent Internatio...

2023-09-20 15:08:03 ET Transgene SA (TRGNF) Q2 2023 Earnings Conference Call September 20, 2023 12:00 PM ET Company Participants Lucie Larguier - Head of Investor Relations Alessandro Riva - Chairman and Chief Executive Officer Jean-Philippe Del - Vice President ...

­ Promising data from ongoing clinical trials of neoantigen cancer vaccine TG4050 and HPV-positive cancer therapeutic vaccine TG4001 presented at key congresses in H1 2023 ­ Immunogenicity clinical data from ongoing trials confirm mechanism of action of Transgene’s ther...

Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it has received $15.3 million (€ 14.0 million) as a result of the full disposal of its minority stake in a Chinese...